Sanofi CFO Jerome Contamine hits the exit; Struggling Fibrocell triggers a strategic review

→ Penny stock biotech Fibrocell Science $FCSC is waving the white flag. Execs have begun a strategic review for the company, and everything is on the table. The gene therapy company based in Exton, PA is open to a sale or reverse merger for anyone looking for a short cut to Nasdaq. It wouldn’t be expensive. The biotech’s market cap has dwindled to $17 million.

Sanofi is preparing for the retirement of  CFO Jerome Contamine, who’s leaving the French drugmaker after almost 10 years in the role. Before he leaves later this year, the company says, Contamine will help identify a successor and guide the transition.

Airway Therapeutics, a spin-out of Cincinnati Children’s Hospital Medical Center, has rounded up an $11 million round from a syndicate of new and existing investors. Their lead drug is AT-100, a recombinant form of human surfactant protein D designed to prevent bronchopulmonary dysplasia in preterm babies.

Andres Gutierrez, the chief medical officer at Oncolytics Biotech, is leaving the company in about a week to “pursue other opportunities.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->